19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Tandem construction of biological relevant aliphatic 5-membered N-heterocycles.
Adam Mickiewicz University
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.
Glaxosmithkline
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Japan Tobacco
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
Chinese Academy of Medical Sciences and Peking Union Medical College
Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
Chemical Diversity Research Institute
Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.
Japan Tobacco
Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
Vertex Pharmaceuticals
Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
Presidio Pharmaceuticals
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
Merck
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.
National Health Research Institutes
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
Gilead Sciences
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
Glaxosmithkline
Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
Lupin
In Praise of Remarkably Powerful Centamolecular Therapeutic Agents.
Bristol-Myers Squibb Research and Development
A review on HCV inhibitors: Significance of non-structural polyproteins.
Institute of Pharmaceutical Education and Research
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
Chia Tai Tianqing Pharmaceutical Group
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
Presidio Pharmaceuticals
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Abbvie